Health Dictionary Find a Doctor

Myeloproliferative neoplasm laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2] Shyam Patel [3]

Overview

Overview

Laboratory findings associated with the diagnosis of myeloproliferative neoplasm include leukocytosis, thrombocytopenia, and anemia.

Laboratory Findings

Laboratory Findings

Laboratory findings associated with myeloproliferative neoplasm include:[1][2][3][4][5][6]

  • Blood chemistry
  • The following blood levels may be elevated:
  • Bleeding and clotting factors
  • The following blood parameters may be elevated:
  • Flow cytometry helps determine the type of cells that are present.
  • Chromosome changes that may occur in some people with leukemia include:
  • Similar to cytogenetics, but more specific for particular chromosomal translocations
  • Polymerase chain reaction
  • Helpful to detect specific abnormalities in blood or bone marrow cells. Abnormalities can be found even if very few leukemia cells are present in a tissue sample.
  • Neutrophil alkaline phosphatase level
  • Vitamin B12 (or B12 binding capacity) level
  • Erythropoietin level
  • Molecular testing for JAK2, CALR, and MPL mutations
Gallery
References

References

  1. Canadian Cancer Society.2015.http://www.cancer.ca/en/cancer-information/cancer-type/leukemia-chronic-myelogenous-cml/diagnosis/?region=ab
  2. James W. Vardiman (2009). “Chronic myelogenous leukemia, BCR-ABL1+”. American journal of clinical pathology. 132 (2): 250–260. doi:10.1309/AJCPUN89CXERVOVH. PMID 19605820. Unknown parameter |month= ignored (help)
  3. Sánchez-Muñoz, Laura; Alvarez-Twose, Ivan; García-Montero, Andrés C; Teodosio, Cristina; Jara-Acevedo, María; Pedreira, Carlos E; Matito, Almudena; Morgado, Jose Mario T; Sánchez, Maria Luz; Mollejo, Manuela; Gonzalez-de-Olano, David; Orfao, Alberto; Escribano, Luis (2011). “Evaluation of the WHO criteria for the classification of patients with mastocytosis”. Modern Pathology. 24 (9): 1157–1168. doi:10.1038/modpathol.2011.84. ISSN 0893-3952.
  4. Levene, Malcolm I.; Lewis, S. M.; Bain, Barbara J.; Imelda Bates. Dacie & Lewis Practical Haematology. London: W B Saunders. p. 586. ISBN 0-443-06377-X.
  5. O’Brien, S. (2004). “Chronic Myelogenous Leukemia and Myeloproliferative Disease”. Hematology. 2004 (1): 146–162. doi:10.1182/asheducation-2004.1.146. ISSN 1520-4391.
  6. Murakami J, Shimizu Y (2013). “Hepatic manifestations in hematological disorders”. Int J Hepatol. 2013: 484903. doi:10.1155/2013/484903. PMC 3626309. PMID 23606974.
  7. Gancheva, Katya; Virchis, Andres; Howard-Reeves, Julie; Cross, Nick CP; Brazma, Diana; Grace, Colin; Kotzampaltiris, Paul; Partheniou, Fedra; Nacheva, Elisabeth (2013). “Myeloproliferative neoplasm with ETV6-ABL1 fusion: a case report and literature review”. Molecular Cytogenetics. 6 (1): 39. doi:10.1186/1755-8166-6-39. ISSN 1755-8166.

Template:WH Template:WS

Looking for the patient version?

Back to the patient-friendly article

© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH